Name: 阿斯利康股價在390億美元的Alexion交易後下挫 (AstraZeneca shares dip after $39 bln Alexion deal)
Uploaded: 2020-12-15T19:25:43.000Z
Duration: 1 min 14 s

shares in AstraZeneca fell around 6% on Monday morning that as investors reacted to news from the firm over the weekend.

阿斯利康股價週一上午下跌約6％，因為投資者對該公司週末的消息作出反應。

The British drugmaker on Saturday announced it's buying Alexion Pharmaceuticals for $39 billion in cash and stock.

英國製藥商周六宣佈以390億美元的現金和股票收購Alexion製藥公司。

S biotech firm makes treatment for rare immune diseases.

S生物技術公司製造治療罕見的免疫疾病。

AstraZeneca CHIEF Pascal Sorry Oh told reporters on Saturday that the company's biggest ever purchase was the result of exclusive talks and added that no competitive bidder was involved.

阿斯利康首席執行官Pascal Sorry Oh週六告訴記者，該公司有史以來最大的收購是獨家會談的結果，並補充說，沒有參與競爭性投標人。

Sorry, oh once AstraZeneca to diversify from its fast growing cancer business.

對不起，哦，曾經阿斯利康要從快速增長的癌症業務中實現多元化發展。

But despite recent speculation about big mergers, some commentators say the election deal is probably not what shareholders were expecting.

不過，儘管最近炒作大合併，但一些評論家表示，選舉交易可能不是股東們所期望的。

AstraZeneca has been busy pushing the group's fast growing cancer business on rolling out a vaccine for Covert 19, while Election specializes in diseases that affect a small number of people.

阿斯利康一直在忙於推動該集團快速增長的癌症業務推出Covert 19的疫苗，而Election則專門研究影響少數人的疾病。

Yet some say the timing looks smart for AstraZeneca, which is worth around $142 billion.

然而有人說，對於價值約1420億美元的阿斯利康來說，這個時機看起來很聰明。

 Its stock is trading at a hefty 21 times expected earnings for next year, according to refer native forecasts That gives it a powerful acquisition. 

根據參考原生的預測，其股價是明年預期收益的21倍，這給了它一個強大的收購。